Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05270083 · ClinicalTrials.gov registry record · NA
Neuraceq™ PET for Detection of Brain Changes in Young Athletes Post-concussion
A NA study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT05270083 is a NA study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 15 participants.
The verdict
NCT05270083, a NA study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of the study is to learn if Neuraceq™ (Florbetaben F 18 Injection) PET can detect changes in the brains of young athletes who sustained one or more concussions with or without persistent cognitive complaints at least 5 years after injury.
Interventions
- DIAGNOSTIC_TEST NeuraCeq PET imaging with intravenous (IV) dose of 300MBq of Neuraceq™ ([F-18]Florbetaben)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-07-13 |
| Est. Completion | 2019-10-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05270083
The ClinicalTrials.gov registry entry for NCT05270083 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NeuraCeq PET imaging with intravenous (IV) dose of 300MBq of Neuraceq™ ([F-18]Florbetaben) is the first listed.
NCT05270083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05270083 about?
NCT05270083 is a clinical study titled "Neuraceq™ PET for Detection of Brain Changes in Young Athletes Post-concussion". The purpose of the study is to learn if Neuraceq™ (Florbetaben F 18 Injection) PET can detect changes in the brains of young athletes who sustained one or more concussions with or without persistent cognitive complaints at least 5 years after injury.
What is the current status of trial NCT05270083?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2017-07-13. Estimated completion is 2019-10-10.
What interventions are being tested in trial NCT05270083?
The interventions under investigation include: NeuraCeq PET imaging with intravenous (IV) dose of 300MBq of Neuraceq™ ([F-18]Florbetaben) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05270083?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.